NO934706L - Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner - Google Patents

Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner

Info

Publication number
NO934706L
NO934706L NO934706A NO934706A NO934706L NO 934706 L NO934706 L NO 934706L NO 934706 A NO934706 A NO 934706A NO 934706 A NO934706 A NO 934706A NO 934706 L NO934706 L NO 934706L
Authority
NO
Norway
Prior art keywords
phenyl
pyridones
substituted
alkoxypyridines
hyperlipoproteinemia
Prior art date
Application number
NO934706A
Other languages
English (en)
Other versions
NO934706D0 (no
Inventor
Rolf Angerbauer
Peter Fay
Walter Hubsch
Thomas Philipps
Hilmar Bischoff
Hans-Peter Krause
Jorg Petersen-Von Gehr
Delf Schmidt
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4321421A external-priority patent/DE4321421A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO934706D0 publication Critical patent/NO934706D0/no
Publication of NO934706L publication Critical patent/NO934706L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksy- pyridiner fremstilles ved at man reduserer tilsvarende 4-fenyl-pyridon- hhv. 4-fenyl-2-alkoksypyridin- derivater. De substituerte 4-fenyl-pyridonene og 4-fenyl-2- alkoksypyridinene kan anvendes som virksomme stoffer i legemidler, spesielt for behandling_ av hyperlipo- proteinemi.
NO934706A 1992-12-21 1993-12-20 Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner NO934706L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4243278 1992-12-21
DE4321421A DE4321421A1 (de) 1992-12-21 1993-06-28 Substituierte 4-Phenyl-pyridone und 4-Phenyl-2-alkoxypyridine

Publications (2)

Publication Number Publication Date
NO934706D0 NO934706D0 (no) 1993-12-20
NO934706L true NO934706L (no) 1994-06-22

Family

ID=25921579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934706A NO934706L (no) 1992-12-21 1993-12-20 Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner

Country Status (21)

Country Link
US (1) US5418243A (no)
EP (1) EP0603649B1 (no)
JP (1) JPH06234741A (no)
CN (1) CN1117965A (no)
AT (1) ATE140226T1 (no)
AU (1) AU660132B2 (no)
CA (1) CA2111778A1 (no)
CZ (1) CZ284093A3 (no)
DE (1) DE59303195D1 (no)
DK (1) DK0603649T3 (no)
ES (1) ES2089687T3 (no)
FI (1) FI935728A (no)
GR (1) GR3020668T3 (no)
HU (1) HUT70150A (no)
IL (1) IL108071A0 (no)
MX (1) MX9308013A (no)
NO (1) NO934706L (no)
NZ (1) NZ250500A (no)
PH (1) PH29953A (no)
PL (1) PL301582A1 (no)
SK (1) SK144893A3 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627420A1 (de) * 1996-07-08 1998-01-15 Bayer Ag 6-(Hydroxymethyl-ethyl)pyridine
JP2005126340A (ja) * 2003-10-22 2005-05-19 Kureha Chem Ind Co Ltd 置換ピリドン類の製造法、その原料化合物及びその製造方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
MX2010002537A (es) * 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
CN104370806B (zh) * 2014-06-17 2017-07-07 中国海洋大学 一种吡啶酮生物碱类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564502A (en) * 1975-07-31 1980-04-10 Smith Kline French Lab Guanidines thioureas and 1,1-diamino-2-nitroethylene derivatives
US4156727A (en) * 1975-07-31 1979-05-29 Smith Kline & French Laboratories Limited Alkoxy pyridine compounds
US4684477A (en) * 1985-03-06 1987-08-04 Chisso Corporation Pyridine derivatives and their use in liquid crystals
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0339342A1 (de) * 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5032602A (en) * 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
DE3909378A1 (de) * 1989-03-22 1990-09-27 Bayer Ag Substituierte biphenyle
DE3925636A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Imino-substituierte pyridine

Also Published As

Publication number Publication date
PH29953A (en) 1996-09-16
FI935728A0 (fi) 1993-12-20
HU9303675D0 (en) 1994-04-28
PL301582A1 (en) 1994-06-27
NO934706D0 (no) 1993-12-20
CA2111778A1 (en) 1994-06-22
FI935728A (fi) 1994-06-22
EP0603649A1 (de) 1994-06-29
ATE140226T1 (de) 1996-07-15
JPH06234741A (ja) 1994-08-23
GR3020668T3 (en) 1996-10-31
US5418243A (en) 1995-05-23
ES2089687T3 (es) 1996-10-01
HUT70150A (en) 1995-09-28
DK0603649T3 (da) 1996-11-04
EP0603649B1 (de) 1996-07-10
CN1117965A (zh) 1996-03-06
SK144893A3 (en) 1995-02-08
AU5195593A (en) 1994-06-30
NZ250500A (en) 1996-02-27
MX9308013A (es) 1994-08-31
DE59303195D1 (de) 1996-08-14
AU660132B2 (en) 1995-06-08
IL108071A0 (en) 1994-04-12
CZ284093A3 (en) 1994-07-13

Similar Documents

Publication Publication Date Title
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
CA2083179A1 (en) Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
MY114889A (en) 1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
IL101145A0 (en) Pharmaceutical compositions containing synergistic combinations of nucleoside derivatives
NL990030I2 (nl) Derivaten en analogen van 2-deoxy-2,3-didehydro-N-acetylneuraminezuur en het gebruik ervan als antivirale middelen.
DE59710893D1 (de) Kosmetische oder pharmazeutische zubereitungen mit vermindertem klebrigkeitsgefühl
AU2740797A (en) Androstene derivatives
NO954878L (no) Pyrrolderivater
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
NO980317L (no) Anvendelse av Calendula-glykosider for behandling av psoriasis
NO952781L (no) Potensiering av temozolomid i humane tumorceller
AU2861389A (en) Disubstituted pyridines
NO960221L (no) 9-substituerte 2-(2-n-alkoksyfenyl)-purin-6-oner
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE59107336D1 (de) Oligosaccharidderivate und deren Verwendung in Heilmitteln
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt
WO1993005807A3 (en) Erythropoietin potentiating agents and methods for their use
CA2003213A1 (en) Antimycotically active cyclopropyl-substituted azolylmethylcarbinols
GR3017967T3 (en) Substituted pyrido-oxazines.
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
NO980175L (no) Anvendelse av kationiske biopolymerer for å fremstille antiflassmidler
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff